Last reviewed · How we verify
Xanthine Oxidase Inhibitor
At a glance
| Generic name | Xanthine Oxidase Inhibitor |
|---|---|
| Also known as | LC350189 |
| Sponsor | LG Chem |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- HLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness (PHASE4)
- A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia (PHASE2)
- Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients (PHASE3)
- Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients (PHASE3)
- Comparative Clinical and Biochemical Study Evaluating the Effectiveness of Metformin Versus Febuxostat on Gouty Obese Non-Diabetic Patients (PHASE2)
- Dose Finding Study to Evaluate Safety and Efficacy of 3 Dosages of SAP 001. (PHASE2)
- Treatment Effects of Chinese Medicine (Yi-Qi-Qing-Jie Herbal Compound) Combined With Immunosuppression Therapies in IgA Nephropathy Patients With High-risk of ESRD (PHASE2, PHASE3)
- Effect of Allopurinol and Febuxostat on Urinary 2,8-Dihydroxyadenine Excretion (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Xanthine Oxidase Inhibitor CI brief — competitive landscape report
- Xanthine Oxidase Inhibitor updates RSS · CI watch RSS
- LG Chem portfolio CI